Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Depreciation: 2023-2024

  • Contineum Therapeutics' Accumulated Depreciation rose 16.25% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year increase of 16.25%. This contributed to the annual value of $1.7 million for FY2024, which is 16.25% up from last year.
  • Contineum Therapeutics' Accumulated Depreciation amounted to $1.7 million in Q4 2024, which was up 16.25% from $1.5 million recorded in Q4 2023.
  • Contineum Therapeutics' Accumulated Depreciation's 5-year high stood at $1.7 million during Q4 2024, with a 5-year trough of $1.5 million in Q4 2023.
  • Its 2-year average for Accumulated Depreciation is $1.6 million, with a median of $1.6 million in 2023.
  • Data for Contineum Therapeutics' Accumulated Depreciation shows a peak YoY rose of 16.25% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' Accumulated Depreciation (Quarterly) stood at $1.5 million in 2023, then increased by 16.25% to $1.7 million in 2024.